The standardization of the potential bone palliation radiopharmaceutical 117mSn(+4)DTPA

Solution containing the potential bone pain palliation radionuclide 117mSn, in chloride form and as a diethylenetriaminepentaacetate (DTPA) complex, have been standardized by 4πβ liquid scintillation (LS) spectrometry and 4π γ-ray spectrometry. massic activities of the stock solutions were measured in order to determine dose calibrator settings for the solutions using commericial dose calibrators. Excellent agreement in the measurement of solution massic activity between the two techniques was achieved. The massic activity of 117mSnCl4 stock solution was found to be 38.62±0.23 MBq g−1 and 38.81 ± 0.94 MBq g− with LS spectrometry and 4π γ-ray spectrometry respectively. The respective values of the massic activity of the 117mSnDTPA stock solution with LS spectrometry and 4π γ-ray spectrometry were 39.35±0.23 MBq g−1 and 39.70 ± 0.96 MBq g−1. Impurities were analyzed in several solutions and found to have emission rates on the order of 10−4 to 10−6 of the rate of the 117mSn emission at the end-of-bombardment. The largest impurities came from 113Sn and 125Sn, the activation products of isotopic impurities present in the 117Sn target. The relative proportions of the various impurities were found to be highly dependent upon the source of 117Sn target material. The implications of choice of half-life used in the decay correction of 117mSn are discussed.